Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

Agree - see how another HARVARD PI gave the feedback and we have been told that Harvard does not comment on their trials and K data cannot be revealed as DF has some special standards.
Looks like it was just b/s - if K data was so compelling DF would have touted it


"“The demonstration of improved overall survival with the therapeutic dose, in combination with 60% durable response rate, is particularly impressive, given this trial focused on women with poor prognosis disease,” said Richard Penson, MD, MRCP, Associate Professor of Medicine, Harvard Medical School, Clinical Director of Medical Gynecologic Oncology, Massachusetts General Hospital, and Primary Investigator for this trial."